ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In the final segment of her interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, described what it means to accumulate inspection readiness throughout development rather than assemble it at the end. The narrative regulators reconstruct during inspection is determined long before the inspection is announced.

• In a contributed article, Lisa Moneymaker, chief operating and strategy officer at Medidata, examined AI churn—repeatedly restarting initiatives before scaling them—as a pattern rooted in organizational execution gaps rather than technology limitations. Breaking the cycle requires defining success upfront, establishing clear ownership and governance, treating adoption as part of the build, and committing to see deployments through to completion with trustworthy data and connected systems.
• In a continuing Pharmaceutical Executive interview, Dr. Richard Graham, chairman and co-founder of TruTechnologies, discussed what would benefit US clinical trials, noting that meaningful global trials are necessary but the core issue is stakeholder misalignment rather than individual initiatives like TrialBlazer. With nine or ten major stakeholders needing to row in the same direction, the US lacks the coordinated approach that distinguishes faster, higher-quality execution in Australia and China.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.